Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moti Ramgopal

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Patient Preference and Adherence|September 12, 2022
Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American ClinicsDuncan Short, Xueqi Wang, Shivali Suri, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
AIDS and Behavior|January 22, 2022
Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American ClinicsDuncan Short, Rob J Fredericksen, Heidi M Crane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 InfectionEdwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
The Lancet. HIV|September 15, 2025
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trialJayani Pathirana, Moti Ramgopal, Charlotte Martin, et al.
AIDS (London, England)|June 11, 2021
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIVCharlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, et al.
The Lancet. HIV|December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
Plos One|November 2, 2017
Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strainsIvette A Nuñez, Michael A Carlock, James D Allen, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
AIDS (London, England)|July 16, 2019
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimenGiuliano Rizzardini, Andrea Gori, Celia Miralles, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Patient Preference and Adherence|September 12, 2022
Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American ClinicsDuncan Short, Xueqi Wang, Shivali Suri, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
AIDS and Behavior|January 22, 2022
Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American ClinicsDuncan Short, Rob J Fredericksen, Heidi M Crane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 InfectionEdwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
The Lancet. HIV|September 15, 2025
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trialJayani Pathirana, Moti Ramgopal, Charlotte Martin, et al.
AIDS (London, England)|June 11, 2021
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIVCharlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, et al.
The Lancet. HIV|December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
Plos One|November 2, 2017
Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strainsIvette A Nuñez, Michael A Carlock, James D Allen, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
AIDS (London, England)|July 16, 2019
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimenGiuliano Rizzardini, Andrea Gori, Celia Miralles, et al.
Pageof 6